Jill Buck
Equibles does not estimate personal net worth.
Get an email with a short summary when enGene Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get ENGN alertsAbout Jill Buck
The proxy statement of Alaunos Therapeutics, Inc. reports total compensation of $1,873,742 for Jill Buck in fiscal 2021, including a base salary of $270,375. enGene Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at enGene Therapeutics Inc. includes Ron Cooper (CEO and Board Member), Ronald H. W. Cooper (CEO and Board Member), Ronald H.W. Cooper (CEO and Board Member) and 7 others.
Affiliation history
-
enGene Therapeutics Inc. (ENGN)
Proxy statement
CurrentStart not stated–present
Last confirmed May 8, 2026
-
Alaunos Therapeutics, Inc. (TCRT)
Proxy statement
Start not stated–2020-05-18
Last confirmed by a filing; no departure on record
Company network
Leadership on record at enGene Therapeutics Inc.
- Ron Cooper CEO, Board Member
- Ronald H. W. Cooper CEO, Board Member
- Ronald H.W. Cooper CEO, Board Member
- Ryan Daws CFO
- Alex Nichols COO
- Alexander Nichols COO
- Dr. Alex Nichols COO
- Anthony Cheung CTO
- Joan Connolly CTO
- Dr. William Grossman Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Alaunos Therapeutics, Inc. (TCRT) | Former EVP, GM Gene Therapy | $270,375 | $1,873,742 |
Recent activity
No call appearances or filed executive changes recorded yet.